Ian Deveau

Deputy Director, Office of Compounding Quality and Compliance (OCQC), Office of Compliance (OC), CDER, FDA Dr. Deveau is the Deputy Director, Compounding Quality in the Office of Compounding Quality and Compliance (OCQC), Office of Compliance, FDA CDER. He oversees efforts to protect the American public from poor quality drug products and ensure compliance of firms authorized by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA). Dr. Deveau is a subject matter expert on sterile drug production, Current Good Manufacturing Practices (21 CFR 210, 211 & 212), and pharmacy compounding practices (USP <795> and <797>). Dr. Deveau holds a Bachelor’s degree in Biology from Buffalo State University and a PhD in Biology from The Pennsylvania State University with minors in Microbiology, Chemistry, and Biochemistry. Prior to joining CDER, he was a Chemist and GLP Study Director at FDA’s Center for Veterinary Medicine (CVM), followed by 9 years at the U.S. Pharmacopeia (USP) involved in developing standards for microbial control of drug manufacturing, blood and blood products, vaccines, biologics and biotechnology products, radiopharmaceuticals & medical imaging agents, and veterinary drugs